Ikatibant Alpha-Medical (Icatibant)

Icatibant competitively blocks the bradykinin B2 receptor, preventing bradykinin from causing vasodilation and increased vascular permeability. This inhibition limits the fluid leakage that leads to the swelling characteristic of hereditary angioedema.

The prescribed dose of Ikatibant Alpha-Medical is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. Dosage instructions are provided on the prescription label and should be followed exactly.

Safety data for icatibant in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other options such as C1‑inhibitor concentrates replace the deficient protein. Icatibant’s mechanism targets the downstream mediator bradykinin, offering rapid symptom relief via subcutaneous injection, while C1‑inhibitor products are administered intravenously.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Ikatibant Alpha-Medical is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.

Serious risks include anaphylaxis, airway angioedema, severe hypotension, and rare cases of injection‑site necrosis. Patients should be monitored closely after administration, and any signs of severe allergic reaction or breathing difficulty require immediate medical attention.

Ikatibant Alpha-Medical should not be used in individuals with known hypersensitivity to icatibant or any excipients in the formulation. Caution is also advised for patients with a history of severe allergic reactions or uncontrolled cardiovascular conditions.